New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers

Trial Profile

New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Oct 2014

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Clarithromycin
  • Indications Acute coronary syndromes; Bacterial infections; Embolism; Stroke
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms DRIVING
  • Most Recent Events

    • 17 Sep 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top